MannKind Corporation [NASDAQ: MNKD] traded at a high on 04/21/21, posting a 9.22 gain after which it closed the day’ session at $4.62. The company report on April 19, 2021 that Mannkind and United Therapeutics Reach a Milestone in the Development of Tyvaso DPI™ With New Drug Application Submitted to the FDA.
Following Afrezza®, Tyvaso DPI is the second compound formulated with Technosphere® technology to be reviewed by FDA.
MannKind Corporation (Nasdaq: MNKD) and United Therapeutics (Nasdaq: UTHR) reached a milestone in the development of Tyvaso DPI™ as United Therapeutics submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA).
The results of the trading session contributed to over 4793964 shares changing hands. Over the past one week, the price volatility of MannKind Corporation stands at 6.66% while the volatility over the past one month is 7.55%.
The market cap for MNKD stock reached $1.18 billion, with 249.07 million shares outstanding and 236.42 million shares in the current float. Compared to the average trading volume of 6.19M shares, MNKD reached a trading volume of 4793964 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about MannKind Corporation [MNKD]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MNKD shares is $6.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MNKD stock is a recommendation set at 1.40. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Oppenheimer have made an estimate for MannKind Corporation shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on December 24, 2019. While these analysts kept the previous recommendation, Cantor Fitzgerald raised their target price to Overweight. The new note on the price target was released on October 25, 2019, representing the official price target for MannKind Corporation stock. Previously, the target price had yet another raise to $3, while BTIG Research analysts kept a Buy rating on MNKD stock.
The Average True Range (ATR) for MannKind Corporation is set at 0.27, with the Price to Sales ratio for MNKD stock in the period of the last 12 months amounting to 18.18.
How has MNKD stock performed recently?
MannKind Corporation [MNKD] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.32. With this latest performance, MNKD shares gained by 25.89% in over the last four-week period, additionally plugging by 131.00% over the last 6 months – not to mention a rise of 275.61% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MNKD stock in for the last two-week period is set at 60.57, with the RSI for the last a single of trading hit 66.26, and the three-weeks RSI is set at 57.15 for MannKind Corporation [MNKD]. The present Moving Average for the last 50 days of trading for this stock 4.36, while it was recorded at 4.30 for the last single week of trading, and 2.92 for the last 200 days.
MannKind Corporation [MNKD]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and MannKind Corporation [MNKD] shares currently have an operating margin of -38.05 and a Gross Margin at +62.17. MannKind Corporation’s Net Margin is presently recorded at -87.87.
Reflecting on the efficiency of the workforce at the company, MannKind Corporation [MNKD] managed to generate an average of -$237,510 per employee. Receivables Turnover for the company is 16.85 with a Total Asset Turnover recorded at a value of 0.64.MannKind Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.00 and a Current Ratio set at 1.10.
Earnings analysis for MannKind Corporation [MNKD]
With the latest financial reports released by the company, MannKind Corporation posted -0.04/share EPS, while the average EPS was predicted by analysts to be reported at -0.06/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 33.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MNKD. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for MannKind Corporation go to 35.60%.
Insider trade positions for MannKind Corporation [MNKD]
There are presently around $318 million, or 30.70% of MNKD stock, in the hands of institutional investors. The top three institutional holders of MNKD stocks are: BLACKROCK INC. with ownership of 17,975,840, which is approximately 1.812% of the company’s market cap and around 0.50% of the total institutional ownership; VANGUARD GROUP INC, holding 12,291,714 shares of the stock with an approximate value of $51.99 million in MNKD stocks shares; and STATE STREET CORP, currently with $37.42 million in MNKD stock with ownership of nearly 137.376% of the company’s market capitalization.
Positions in MannKind Corporation stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 84 institutional holders increased their position in MannKind Corporation [NASDAQ:MNKD] by around 17,431,661 shares. Additionally, 56 investors decreased positions by around 11,050,359 shares, while 29 investors held positions by with 46,760,233 shares. The mentioned changes placed institutional holdings at 75,242,253 shares, according to the latest SEC report filing. MNKD stock had 31 new institutional investments in for a total of 7,928,599 shares, while 19 institutional investors sold positions of 6,696,746 shares during the same period.